MedPath

Kalytera Therapeutics Israel, Ltd.

Ownership
Private
Employees
-
Market Cap
-
Website

Clinical Trials

1

Active:0
Completed:0

Trial Phases

1 Phases

Phase 2:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Phase 2
1 (100.0%)

An Open Label Study of Multiple Doses of Cannabidiol in the Prevention of Acute Graft-Versus-Host Disease (GVHD)

Phase 2
Conditions
Prevention aGVHD
Interventions
First Posted Date
2019-02-15
Last Posted Date
2021-09-01
Lead Sponsor
Kalytera Therapeutics Israel, Ltd.
Target Recruit Count
36
Registration Number
NCT03840512
Locations
🇦🇺

St Vincent's Hospital Sydney - The Kinghorn Cancer Centre, Sydney, Australia

🇮🇱

Rambam Health Care - Bone Marrow Transplantation Unit, Haifa, Israel

🇮🇱

Hadassah Medical Center - Bone Marrow Transplantation Department, Cancer Immunotherapy and Immunobiology Research Center, Jerusalem, Israel

and more 2 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.